The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against INSYS Therapeutics, Inc. (Nasdaq: INSY) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
On December 12, 2013, the Company disclosed that it has received a subpoena from the Office of Inspector General of the Department of Health and Human Services (HHS) regarding an investigation of potential violations involving HHS programs. The subpoena concerns Subsys®, including INSYS' sales and marketing practices relating to this product. On this news, shares of INSYS fell $7.56 per share, or by approximately 17%, during intraday trading on December 13, 2013.
The Rosen Law Firm is preparing a class action lawsuit as a result of this adverse information. If you purchased INSYS securities, you may visit the website at
to join the action. You may also contact Phillip Kim, Esq. or Jonathan Horne, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.